Clinical Trials in Illinois

Showing 8461-8480 of 19,692 trials

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02333188

This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that has spread to other parts of the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.

Adenocarcinoma of Unknown PrimaryAdult CholangiocarcinomaGallbladder Carcinoma+14 more

University of Chicago50 participantsStarted Dec 2014

Chicago, Illinois, United States • Decatur, Illinois, United States • Evanston, Illinois, United States +5 more locations

COMPLETEDPhase 140 miles

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

NCT03075670

This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.

Congenital Bleeding DisorderHaemophilia B

Novo Nordisk A/S15 participantsStarted Mar 2017

Phoenix, Arizona, United States • Chicago, Illinois, United States • Peoria, Illinois, United States +9 more locations

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Find Trials by Condition in Illinois

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

Study of Diroximel Fumarate in the Real-World Setting

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans

Implementing Personal Health Records to Promote Evidence-Based Cancer Screening

Aligning Medications With What Matters Most

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer